Sunday, July 3, 2022

561.316.3330

Paul Chu, MBA, Appointed VP of Business Development at Phanes Therapeutics

Mr. Paul Chu, MBA, as Vice President of Business Development.

“We welcome Paul to the Phanes family and are delighted to appoint a professional of his caliber as Vice President of Business Development,” said Dr. Ming Wang, Founder and CEO. “We have built a strong pipeline in immuno-oncology by leveraging our proprietary technology platforms and expect to file 3 INDs in 2022, including one best-in-class monoclonal antibody (mAb) program and two first-in-class bispecific antibody programs. We look forward to benefitting from Paul’s extensive experience and network in Oncology as we enter 2022 which we expect to be a transformational year for Phanes.”

Mr. Chu has extensive experience in pharma and biotech licensing, collaborations, acquisitions, and strategy. He has held senior leadership roles in both small biotech companies and large multi-national corporations and has closed deals valued at over $6 billion with a portfolio that spans across oncology, eyecare, neuroscience, and medical aesthetics. Prior to joining Phanes, Mr. Chu was Vice President of Business Development at HUYABIO International where he in-licensed two oncology assets for development in solid tumors. Prior to HUYABIO, Mr. Chu held similar roles at AiViva BioPharma and UroGen Pharma and earlier in his career was Director of Business Development at Allergan, Inc. where he spearheaded multiple M&A transactions.

Mr. Chu holds an MBA from the University of Southern California’s Marshall School of Business and a BA in Finance and Business Administration from California State University, Fullerton.

Other News of Interest

For executives on the move click here.
For all Biotechnology news, click here.
Pharma news can be found here.
For clinical trials and updates, click here.
FDA update news, click here.
For mergers and acquisitions, click here.
For funding, click here.